(Q36693843)

15 August 2017

1 reference

title

Micafungin: a new echinocandin antifungal (English)

1 reference

15 August 2017

Jomy M Joseph

1

1 reference

15 August 2017

Rupali Jain

series ordinal

2

1 reference

15 August 2017

Larry H Danziger

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

27

1 reference

15 August 2017

1

1 reference

15 August 2017

53-67

1 reference

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

15 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Safety and tolerability of caspofungin acetate in the treatment of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibilit

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Efficacy of micafungin alone or in combination against systemic murine aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Amphotericin B: time for a new "gold standard".

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Voriconazole salvage treatment of invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Successful treatment of invasive aspergillosis in two patients with acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.1.53

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.1.53

1 reference

15 August 2017

1 reference